Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Ноя. 14, 2024

Abstract In the last decade, messenger ribonucleic acid (mRNA)-based drugs have gained great interest in both immunotherapy and non-immunogenic applications. This surge can be largely attributed to demonstration of distinct advantages offered by various mRNA molecules, alongside rapid advancements nucleic delivery systems. It is noteworthy that immunogenicity presents a double-edged sword. context immunotherapy, extra supplementation adjuvant generally required for induction robust immune responses. Conversely, non-immunotherapeutic scenarios, activation unwanted considering host tolerability high expression demand mRNA-encoded functional proteins. Herein, mainly focused on linear non-replicating mRNA, we overview preclinical clinical progress prospects medicines encompassing vaccines other therapeutics. We also highlight importance focusing host-specific variations, including age, gender, pathological condition, concurrent medication individual patient, maximized efficacy safety upon administration. Furthermore, deliberate potential challenges may encounter realm disease treatment, current endeavors improvement, as well application future advancements. Overall, this review aims present comprehensive understanding mRNA-based therapies while illuminating prospective development drugs.

Язык: Английский

---

Management of patients with neurological diseases considering post‐pandemic coronavirus disease 2019 (COVID‐19) related risks and dangers — An updated European Academy of Neurology consensus statement

European Journal of Neurology, Год журнала: 2024, Номер 31(10)

Опубликована: Авг. 1, 2024

In October 2020, the European Academy of Neurology (EAN) consensus statement for management patients with neurological diseases during coronavirus disease 2019 (COVID-19) pandemic was published. Due to important changes and developments that have happened since then, need has arisen critically reassess original recommendations address new challenges.

Язык: Английский

---

Navigating Coronavirus Disease 2019 in Immunocompromised Populations

Infectious Disease Clinics of North America, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

---

The equitable aging in health conceptual framework: international interventions infusing power and justice to address social isolation and loneliness among older adults

Frontiers in Public Health, Год журнала: 2025, Номер 13

Опубликована: Март 10, 2025

Introduction Social isolation and loneliness among older adults have garnered significant international attention, particularly as structures services evolved during a global pandemic. A growing body of research underscores disparities in social intersecting (e.g., race, ethnicity, age, gender, sexual orientation, disability) physical rural/urban) locations. While empirical data about these trends has increased, conceptual theoretical frameworks are underdeveloped loneliness, especially from perspective. This article presents novel equitable aging framework to help contextualize, understand, explain how power influences adults. Equitable health builds on principles critical gerontology, public concepts political determinants health, human rights, intersectionality present new for researchers, policymakers, practitioners. centers five domains (intrapersonal, interpersonal, disciplinary, structural, cultural) components (or hub) that drive six (economic stability, education access quality, care neighborhood built environment, community context, laws politics). The sixth determinant (laws policies) incorporates rights (economic, social, cultural, civil, rights). When justice is infused power, can produce outcomes. Aging Health Framework tool understand ultimately achieve opportunities connections Discussion To illustrate the utility this framework, case studies interventions China, Taiwan, Spain, Sweden, Mexico, United States employ address diverse communities These propose services, programs, policies infuse different paradigms various ways build support

Язык: Английский

---

Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective

Infectious Diseases and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Март 18, 2025

Immunocompromised patients are disproportionately impacted by severe disease, hospitalization, and mortality associated with coronavirus disease 2019 (COVID-19). To optimize the management of these in clinical practice, we convened an expert panel to review current evidence on acute respiratory syndrome 2 (SARS-CoV-2) vaccine responses COVID-19 immunocompromised populations. We identified four main groups—solid organ transplant recipients, receiving allogeneic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T therapy, treated for hematologic malignancies, inflammatory diseases—who mount suboptimal humoral SARS-CoV-2 vaccination at increased risk COVID-19-related outcomes. A wide range factors were reduced and/or poor outcomes, most commonly older age, comorbidities, type number immunosuppressive therapies. believe that early identification close monitoring at-risk patients, plus regular booster vaccinations, prophylactic monoclonal antibody non-pharmacologic prevention measures, prompt antiviral treatment, other mitigation strategies, critical protect against infection COVID-19. Although people will fully recover from COVID-19, who less able fight more likely be hospitalized die improve treatment people, 10 experts France met discuss latest medical research this area. The focused groups people: (1) transplants; (2) transplants therapy; (3) being blood cancers; (4) diseases (such as rheumatoid arthritis). These protected after develop forms pre-existing conditions diabetes, obesity, heart, lung, kidney disease), immunosuppressants. agreed it is important quickly identify clinic, so they can receive vaccines every 6 months. For unable build up their immunity vaccination, treatments also used prevent infection. In recommend using therapies nirmatrelvir/ritonavir remdesivir) becoming severe. addition measures mask wearing social distancing), strategies help

Язык: Английский

---

Fresh frozen plasma for neutralizing SARS-CoV-2: “An exploratory cross-sectional study and review of the state of the art”

Enfermedades Infecciosas y Microbiología Clínica, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

---

The DESTINIES Study: an online Delphi study to build international consensus on the medical conditions and procedures that confer immunosuppression and their respective COVID-19 risk profiles

EClinicalMedicine, Год журнала: 2025, Номер 83, С. 103239 - 103239

Опубликована: Май 1, 2025

The lack of international consensus on defining and categorising immunosuppression has undermined disease surveillance patient care, particularly during the COVID-19 pandemic. To address this, a global expert panel was recruited to join eDElphi STudy fully defiINe COVID-risk stratify ImmunosupprESsion (DESTINIES) develop COVID risk-stratified digital phenotype for 'adult immunosuppression' (the DESTINIES phenotype). Panellists were presented with all medical diagnoses procedures cited in prevailing immunosuppressed definitions; they evaluated their appropriateness risks severe outcomes through anonymous online questionnaires discussion. Panel agreement series clinical statements also assessed; incorporated longstanding disputes, including variables that could reverse immunosuppression. Each round data collection informed refined draft until final ratification. This study active between May September 2024. Sixty-four experts from four continents 12 agencies completed two rounds questionnaire, discussion group ratifying vote. identified candidates posing higher (e.g. Transplantation, Primary Immunodeficiency) lower risk Anorexia nervosa, Cerebral spinal fluid leak) but disagreed categorisation others Asplenia, Immune-mediated Inflammatory Disease). Consensus reached ten statements, notably removing Drug-managed HIV Cancer remission consideration as immunosuppressed. ratified near unanimous support (94%) implementation surveillance. Pending validation, provides clinically meaningful, internationally digitally practical method identifying risk-stratifying adult patients healthcare data. work funded by UK Medical Research Council EMIS Health.

Язык: Английский

---

Fresh frozen plasma for neutralizing SARS-CoV-2: “An exploratory cross-sectional study and review of the state of the art”

Enfermedades infecciosas y microbiologia clinica (English ed ), Год журнала: 2025, Номер 43(5), С. 282 - 290

Опубликована: Май 1, 2025

Язык: Английский

---

Longitudinal assessment of COVID-19 vaccine immunogenicity in people with HIV stratified by CD4+ T-cell count in the Netherlands: A two-year follow-up study

PLoS ONE, Год журнала: 2025, Номер 20(5), С. e0323792 - e0323792

Опубликована: Май 19, 2025

Background Although guidelines for COVID-19 additional vaccination strategies generally prioritise people with advanced HIV infection, recommendations vary globally, some countries recommending an annual all (PWH), while others restrict this to PWH a CD4 + T-cell count < 200 cells per µL. Methods We conducted prospective cohort study in 448 adult PWH. The primary outcome was the SARS-CoV-2 spike (S1)-specific IgG antibody level at 1, 6, 12, 18, and 24 months after completing series (two doses of BNT162b2, mRNA-1273, or ChAdOx1-S, one dose Ad26.COV2.S). compared kinetics over two years between baseline µL (n = 16) vs. ≥ 432) mixed-effects model. Secondary outcomes included variables associated S1-specific levels incidence breakthrough infections. Results median most recent prior 140 (IQR 80–165) group, 688 520–899) group time vaccination. antibodies were lower during two-year follow-up, predicted 514 (95% CI 456–578) 2758 1488–5110) BAU mL 12 (p 0.001) 839 732–959) 3505 1712–7175) 0.001). overall infections 55% comparable groups. A µL, higher age, vector-based negatively time. Conclusion Long-term humoral responses those National vaccine booster vaccines PWH, should therefore specifically emphasise need Trial registration: trial registered on International Clinical Trials Platform (registration number: EUCTR2021-001054-57-N).

Язык: Английский

---

COVID-19 mortality amongst the immunosuppresed

Journal of Infection, Год журнала: 2024, Номер 88(4), С. 106137 - 106137

Опубликована: Март 11, 2024

Язык: Английский

---